Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883–893.
   PubMed Web of Science ®Google Scholar
• Sigal DS, Miller HJ, Schram ED, et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 2010;116: 2884–2896.
   PubMed Web of Science ®Google Scholar
• Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5’-triphosphate. Cancer Res 1991;51: 2386–2394.
   PubMed Web of Science ®Google Scholar
• Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996; 56:3030–3037.
   PubMed Web of Science ®Google Scholar
• Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2’-arabino-fluoro-2’-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438–2444.
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855–863.
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2’-arabino-fluoro-2’-deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970–2974.
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537–3543.
   PubMed Web of Science ®Google Scholar
• Blum KA, Hamadani M, Phillips GS, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:349–356.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Davis N, Bitran JD, et al. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer 2011;117:1490–1497.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790–794.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Kim KM, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10: 28–32.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694–704.
   PubMed Web of Science ®Google Scholar
• Tulpule A, Schiller G, Harvey-Buchanan LA, et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer 1998;83:2370–2376.
   PubMed Web of Science ®Google Scholar
• Kong LR, Huang CF, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma. Cancer 1998;82: 957–964.
   PubMed Web of Science ®Google Scholar
• Nagai H, Ogura M, Kusumoto S, et al. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Eur J Haematol 2011;86:117–123.
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15: 110–115.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2006;24:174–180.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145:344–349.
   PubMed Web of Science ®Google Scholar